1-5 of 5
Satianand Ramnarain, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics

Gertjan J.L. Kaspers, MD PhD, Denise Niewerth, PhD, Bram Wilhelm, PharmD, Satianand Ramnarain, MSc, Hans Berkhof, PhD, Valerie De Haas, MD PhD, Ron A.A. Mathôt, PharmD, PhD, Andishe Attarbaschi, MD, Andre Baruchel, MD, Eveline S. de Bont, Franca Fagioli, MD, Claudia Rossig, MD, Thomas Klingebiel, MD, Barbara De Moerloose, MD PhD, Brigitte Nelken, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD, Pierre Simon Rohrlich, MD, Pauline Simon, MD, Arend Stackelberg, MD, C. Michel Zwaan, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2501.
https://doi.org/10.1182/blood.V126.23.2501.2501
Published: 2015
Journal Articles

Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium

Christian M. Zwaan, MD PhD, Michael Dworzak, MD PhD, Thomas Klingebiel, MD, Claudia Rössig, MD, Guy Leverger, MD, Jan Stary, Evelina S. de Bont, MDPhD, Satianand Ramnarain, MSc, Yves Bertrand, MD, Benoit Brethon, MD, Brigitte Strahm, MD, Gertjan J. Kaspers, MD PhD, Dirk Reinhardt, MD PhD
Journal: Blood
Blood (2014) 124 (21): 989.
https://doi.org/10.1182/blood.V124.21.989.989
Published: 2014
Journal Articles

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Gertjan Kaspers, MD PhD, Denise Niewerth, MSc, Satianand Ramnarain, MSc, Andishe Attarbaschi, MD, André Baruchel, MD, Evelina S De Bont, MDPhD, Franca Fagioli, MD, Barbara De Moerloose, MD PhD, Karsten Nysom, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD PhD, Pierre-Simon Rohrlich, MDPhD, Pauline Simon, MD, Arend von Stackelberg, MD, C. Michel Zwaan, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2290.
https://doi.org/10.1182/blood.V124.21.2290.2290
Published: 2014
Journal Articles

Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium

Christian M. Zwaan, Michael Dworzak, Thomas Klingebiel, MD, Claudia Rossig, MD, Guy Leverger, MD, Jan Stary, Evelina S. De Bont, MD, PhD, Satianand Ramnarain, MSc, Yves Bertrand, MD, Essam A Ghazaly, MD, Dirk Reinhardt
Journal: Blood
Blood (2013) 122 (21): 2693.
https://doi.org/10.1182/blood.V122.21.2693.2693
Published: 2013
Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan
Journal: Blood
Blood (2013) 122 (21): 1439.
https://doi.org/10.1182/blood.V122.21.1439.1439
Published: 2013